Article

Alcon launches new NSAID

Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.

 

Fort Worth, TX-Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.

In two double-masked, randomized clinical trials, the NSAID demonstrated superior clinical efficacy compared with its vehicle. Patients treated with product were less likely to have ocular pain and measurable signs of inflammation (cells and flare) at the end of treatment. Researchers found faster resolution of both inflammation and pain with the experimental medication.

 “Effective management of pain and inflammation associated with cataract surgery is a priority for me,” said Stephen Lane, MD, adjunct clinical professor of ophthalmology, University of Minnesota, and medical director, Associated Eye Care, Minneapolis. “I am confident that this highly effective option, with its innovative formulation, will benefit my patients.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

Related Videos
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.